Access cutting-edge cancer treatment through this clinical trial at a research site in Boston. Study-provided care at no cost to qualified participants.
Access cancer specialists in Boston at no cost
This study follows strict safety protocols and ethical guidelines
All study-related cancer treatment provided free
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastoma and in pediatric and young adult participants with Ewing sarcoma.
Sponsor: Merck Sharp & Dohme LLC
Check if you qualify for this cancer clinical trial in Boston, MA
If you're searching for cancer treatment options in Boston, MA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Boston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.